- Actavis seeks approval for generic opioid-dependence drug
- FDA advisory committees vote against changing naproxen label to highlight a lower CVD profile
- Reckitt Benckiser talks about Mucinex, Airborne line extensions
- New York's online database of drug prescriptions curtailing 'doctor shopping'
- CVS Caremark to stop selling tobacco in all store locations
AMITYVILLE, N.Y. Hi-Tech Pharmacal will market a generic version of a drug used to treat opioid dependence, the company said Monday.
Hi-Tech announced that it would market buprenorphine hydrochloride in the 2-mg and 8-mg strengths through its Midlothian Labs division. The drug is in the form of a tablet placed under the tongue.
The tablets are a generic version of Reckitt Benckiser’s Subutex, which had sales of $75 million during the 12-month period ended in June, according to IMS Health.